A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.

Cardiovasc Diabetol · 2015 · PMC4324641 · PMID 25645672

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

Second generation glibenclamide and glipizide are extensively used and are known to have a quite significant risk of hypoglycaemia [ 19 , 20 ].

also in 5,695 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.